HCM
TTRX

Hodges Capital Management’s Turn Therapeutics TTRX Stock Holding History

Hodges Capital Management’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$32K – 240
2026
Q1 		$32K Hold
10,000
– – ﹤0.01% 198
2025
Q4 		$39.4K Buy
+10,000
New +$41.7K ﹤0.01% 193

Other funds holding TTRX

SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
DI
DDFG Inc Thousand Oaks, California $504M AUM 18.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BA
Bridgewater Advisors New York $1.83B AUM 22.9% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $1.07B AUM 26.86% 1-Year Est. Return

Hodges Capital Management's TTRX Position: Q2 2026 in Review

Hodges Capital Management sold out of Turn Therapeutics (TTRX) in Q2 2026, closing a stake of 10,000 shares — an estimated $32K sold.

Hodges Capital Management first reported a position in TTRX in Q4 2025 and held it in 2 quarters. The position peaked at $39.4K in Q4 2025. 29 funds tracked by Wall St. Rank hold TTRX as of Q2 2026.

  • Hodges Capital Management reported no remaining Turn Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hodges Capital Management sold 10,000 Turn Therapeutics shares in Q2 2026, an estimated $32K.
  • Hodges Capital Management first reported a position in Turn Therapeutics in Q4 2025 and held it in 2 quarters.
  • Hodges Capital Management's Turn Therapeutics position peaked at $39.4K in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Turn Therapeutics as of Q2 2026.

Based on Hodges Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.